ライフサイエンスコーパス: major histocompatibility

1 Expression of major histocompatibility antigens class-2 (MHC-II) under

2 ained by increased recipient mismatching for major histocompatibility antigens or minor histocompatib

3 rm acceptance of cardiac allografts across a major histocompatibility barrier.

4 D in a murine model of allogeneic HCT across major histocompatibility barriers.

5 croglobulin (beta2m), a key component of the major histocompatibility class I complex, can aggregate

6 The major histocompatibility class I-like antigen-presenting

7 after CNS injury can occur independently of major histocompatibility class II (MHCII) signaling to T

8 the affinity of CD4 for its ligand, peptide-major histocompatibility class II (pMHC II) on antigen-p

9 Q61K and BRAFV600E, causes expression of the major histocompatibility class II antigen presentation a

10 d expression of CIITA, a master regulator of major histocompatibility class II gene transcription.

11 In patients, expression of major histocompatibility class II in melanoma is linked

12 ens (SAgs), which engage lateral surfaces of major histocompatibility class II molecules and T-cell r

13 Whereas major histocompatibility class-1 (MH1) proteins present

14 control region (chromosome 5q31.1), and the major histocompatibility complex (chromosome 6p21-22).

15 icant (P < 2.5e-05) vGWAS signals within the major histocompatibility complex (MHC) across all three

16 ion of primary Sjogren's syndrome (pSS) with Major Histocompatibility Complex (MHC) alleles is quinte

17 likelihood of neoantigen presentation by the major histocompatibility complex (MHC) and subsequent re

18 The skin constructs were transplanted across major histocompatibility complex (MHC) barriers in a por

19 ll (DC) maturation, as well as inhibition of major histocompatibility complex (MHC) class I and class

20 at BDLF3 downregulates expression of surface major histocompatibility complex (MHC) class I and class

21 rogates tumour antigen peptides presented by major histocompatibility complex (MHC) class I and class

22 The direct major histocompatibility complex (MHC) class I antigen p

23 Here we found a central role for major histocompatibility complex (MHC) class I in contro

24 munoglobulin-like receptors (KIRs) and their major histocompatibility complex (MHC) class I ligands.

25 Individuals expressing the major histocompatibility complex (MHC) class I molecule

26 ating receptors, many of which interact with major histocompatibility complex (MHC) class I molecules

27 Major histocompatibility complex (MHC) class I molecules

28 s long, are presented at the cell surface by major histocompatibility complex (MHC) class I molecules

29 ification of peptides that were presented on major histocompatibility complex (MHC) class I molecules

30 nting exogenous antigens to T cells via both major histocompatibility complex (MHC) class I pathways

31 Peptide antigen presentation by major histocompatibility complex (MHC) class I proteins

32 These cells also had decreased expression of major histocompatibility complex (MHC) class I proteins,

33 f G-protein signaling, and downregulation of major histocompatibility complex (MHC) class I surface e

34 ed cells is characteristically restricted by major histocompatibility complex (MHC) class I, although

35 killer cells express multiple receptors for major histocompatibility complex (MHC) class I, includin

36 c acid early inducible-1 (Rae-1) in mice and major histocompatibility complex (MHC) class I-chain-rel

37 Rs recognize lipid antigens presented by the major histocompatibility complex (MHC) class I-like mole

38 ds (NKG2DLs) are a group of stress-inducible major histocompatibility complex (MHC) class I-like mole

39 Innate variant TFH cells required major histocompatibility complex (MHC) class I-like sign

40 lized type of proteasome destined to improve major histocompatibility complex (MHC) class I-mediated

41 This study investigated the role of major histocompatibility complex (MHC) class I-related c

42 ors of bacterial riboflavin presented by the major histocompatibility complex (MHC) class I-related m

43 ost current strategies use genes that encode major histocompatibility complex (MHC) class I-restricte

44 as a model, we found that the expression of major histocompatibility complex (MHC) class II and CD74

45 Suppression of major histocompatibility complex (MHC) class II antigen

46 with pools of dengue virus-derived predicted major histocompatibility complex (MHC) class II binding

47 produces antigenic peptides for loading onto major histocompatibility complex (MHC) class II molecule

48 distinguished CD4(+) T cells selected by the major histocompatibility complex (MHC) class II molecule

49 HD, we show that antigen presentation within major histocompatibility complex (MHC) class II of donor

50 Recently, major histocompatibility complex (MHC) class II tetramer

51 resentation, including the gene encoding the major histocompatibility complex (MHC) class II transact

52 Because major histocompatibility complex (MHC) class II(+) cells

53 on the basis of their expression levels and major histocompatibility complex (MHC) class II-binding

54 ted lymphocytes to be targeted by a panel of major histocompatibility complex (MHC) class II-matched

55 B cells, CD11b(+) myeloid-derived cells, and major histocompatibility complex (MHC) class II-positive

56 nce in renal infiltration with ED1 (CD68) or major histocompatibility complex (MHC) class II-positive

57 In a complementary approach, we generated major histocompatibility complex (MHC) class II-restrict

58 Also, individuals with locally rare major histocompatibility complex (MHC) class IIb genotyp

59 The major histocompatibility complex (MHC) contains the most

60 ter bone marrow transplantation (BMT) across major histocompatibility complex (MHC) disparities and m

61 Genes of the major histocompatibility complex (MHC) encode receptor m

62 Previous studies have indicated that the major histocompatibility complex (MHC) genes play the mo

63 a unique group of animals that have limited major histocompatibility complex (MHC) genetic diversity

64 t retain immunogenicity depends on both host major histocompatibility complex (MHC) genetics and the

65 ngest association with AD risk occurred with major histocompatibility complex (MHC) haplotype A*03:01

66 scuous crossreactivity toward multiple other major histocompatibility complex (MHC) haplotypes.

67 The chicken major histocompatibility complex (MHC) has strong geneti

68 Disruption of the non-classical Major Histocompatibility Complex (MHC) Ib molecule Qa-1

69 can operate simultaneously by analysing the major histocompatibility complex (MHC) in guppies (Poeci

70 The T cell antigen receptor (TCR)-peptide-major histocompatibility complex (MHC) interface is comp

71 The Major Histocompatibility Complex (MHC) is a key componen

72 The binding between a peptide and a major histocompatibility complex (MHC) is one of the mos

73 Continuous contact with self-major histocompatibility complex (MHC) ligands is essent

74 1 at microsatellite, structural variant, and major histocompatibility complex (MHC) loci, confirming

75 a population level involves variation in the major histocompatibility complex (MHC) locus, but the ge

76 in and its feasibility in a clinical setting.Major histocompatibility complex (MHC) matching improves

77 ameliorates cGVHD in multiple models: a full major histocompatibility complex (MHC) mismatch model of

78 Evidence is mounting that the major histocompatibility complex (MHC) molecule HLA-F (h

79 6 haplotype encoding the HLA-C*08:02 class I major histocompatibility complex (MHC) molecule.

80 e antigen when presented in the context of a major histocompatibility complex (MHC) molecule.

81 receptor (TCR) and peptide presented by the major histocompatibility complex (MHC) molecule.

82 n of protein antigens on the cell surface by major histocompatibility complex (MHC) molecules coordin

83 (TCR) and antigenic peptide in complex with major histocompatibility complex (MHC) molecules is a cr

84 alphabeta T cell receptor (TCR) with peptide-major histocompatibility complex (MHC) molecules on anti

85 lls respond to peptide epitopes presented by major histocompatibility complex (MHC) molecules.

86 ertoire interacts with peptides presented by major histocompatibility complex (MHC) molecules.

87 ones and was largely restricted by classical major histocompatibility complex (MHC) molecules.

88 Here we use peptide-major histocompatibility complex (MHC) multimers labeled

89 Major Histocompatibility Complex (MHC) or Human Leukocyt

90 ttributable to either a TCR focus on exposed major histocompatibility complex (MHC) polymorphisms or

91 Sequence-based analyses of major histocompatibility complex (MHC) polymorphisms rev

92 nsion that was dependent on the nonclassical major histocompatibility complex (MHC) protein CD1d, whi

93 immune response process is regulated by the major histocompatibility complex (MHC) protein which is

94 gth with which complexes of self peptide and major histocompatibility complex (MHC) proteins are reco

95 T cells reactive to complexes of peptide and major histocompatibility complex (MHC) proteins, many ot

96 d variants expanding throughout the extended major histocompatibility complex (MHC) region and 68 non

97 The mammalian Major Histocompatibility Complex (MHC) region contains s

98 Multiple single variants within the major histocompatibility complex (MHC) region were obser

99 ongly influenced by genetic variation in the major histocompatibility complex (MHC) region.

100 41270488) for HPV8 seropositivity within the major histocompatibility complex (MHC) region.

101 oci, with the strongest association from the major histocompatibility complex (MHC) region.

102 ant associations, in the IL28B/IFNL4 and the major histocompatibility complex (MHC) regions, with spo

103 Major histocompatibility complex (MHC) restriction is a

104 Major histocompatibility complex (MHC) restriction is a

105 variant mapping, independent localization of major histocompatibility complex (MHC) risk from classic

106 ines were up to 94.4% pure, as determined by major histocompatibility complex (MHC) tetramer analysis

107 , including the tumor necrosis factor (TNF), major histocompatibility complex (MHC), interleukin 23 r

108 nt, have been implicated in vertebrates: the major histocompatibility complex (MHC), which could be v

109 and recipients, most prominently within the major histocompatibility complex (MHC), which encodes hu

110 Here we identified 107 major histocompatibility complex (MHC)-bound HIV peptide

111 is attributed to an absence of cell surface major histocompatibility complex (MHC)-I molecule expres

112 We now show that major histocompatibility complex (MHC)-II and its master

113 Here we show the efficacy of major histocompatibility complex (MHC)-matched allogenei

114 Our current understanding of major histocompatibility complex (MHC)-mediated antigen

115 In a full major histocompatibility complex (MHC)-mismatched, multi

116 o generate diverse T cell subsets, including major histocompatibility complex (MHC)-restricted alphab

117 shown strong evidence of association to the major histocompatibility complex (MHC).

118 One interesting example is the chicken major histocompatibility complex (MHC).

119 This enrichment was driven by the major histocompatibility complex (MHC).

120 stinct from interactions between the TCR and major histocompatibility complex (MHC).

121 imal models, have become synonymous with the major histocompatibility complex (MHC).

122 g B-cell selection by sensing the density of major histocompatibility complex (MHC):peptide antigen c

123 ression of IL-12, and inhibition of class II major histocompatibility complex (MHC-II) molecules in i

124 T-cell receptor (TCR) with a peptide-loaded major histocompatibility complex (p/MHC) leads to T-cell

125 s ceased progressively with lowering peptide major histocompatibility complex (pMHC) affinity.

126 thin which T cell receptor (TCR) and peptide major histocompatibility complex (pMHC) interact.

127 This interaction of pre-TCR with peptide-major histocompatibility complex (pMHC) molecules has re

128 encounters its antigenic ligand, the peptide-major histocompatibility complex (pMHC), on the surface

129 f TCR sequences using a panel of peptide and major histocompatibility complex (pMHC)-tetramer-sorted

130 her factors aside from intrinsic TCR-peptide-major histocompatibility complex (TCR-peptide-MHC) react

131 ciation of Parkinson's disease with specific major histocompatibility complex alleles.

132 cell responses upon antigen presentation by major histocompatibility complex and cognate alphabeta T

133 Polymorphisms related to the major histocompatibility complex and interferon (IFN)-ga

134 n of the transmembrane complexes between the major histocompatibility complex and the T cell receptor

135 antibody-mediated TRALI induced by the anti-major histocompatibility complex antibody 34-1-2s.

136 he variable nature of this protein, a common major histocompatibility complex class (MHC-II) epitope

137 M subtypes for their ability to downregulate major histocompatibility complex class A (MHC-A) and MHC

138 6 was markedly more effective at suppressing major histocompatibility complex class I (MHC I) display

139 our cells depends on antigen presentation by major histocompatibility complex class I (MHC I) molecul

140 Major histocompatibility complex class I (MHC I) positiv

141 Certain major histocompatibility complex class I (MHC-I) alleles

142 0I, unexpectedly and uniquely degraded Nef's major histocompatibility complex class I (MHC-I) downreg

143 LCMV V35A) bearing a mutation in the cognate major histocompatibility complex class I (MHC-I) epitope

144 Flow cytometry analyses showed decreased major histocompatibility complex class I (MHC-I) express

145 inactivating mutations that lead to loss of major histocompatibility complex class I (MHC-I) express

146 The NLR family member NLRC5 regulates major histocompatibility complex class I (MHC-I) express

147 Peptide loading of major histocompatibility complex class I (MHC-I) molecul

148 inst NS5 were also elicited, as evidenced by major histocompatibility complex class I (MHC-I) tetrame

149 The NKR-P1B:Clr-b interaction represents a major histocompatibility complex class I (MHC-I)-indepen

150 n subjects with ALS reduce the expression of major histocompatibility complex class I (MHCI) molecule

151 Major histocompatibility complex class I (MHCI) proteins

152 iated immunity is the recognition of peptide-major histocompatibility complex class I (p-MHC I) prote

153 ic interaction affinity with cognate peptide-major histocompatibility complex class I (pMHCI).

154 blood mononuclear cell DEGs associated with major histocompatibility complex class I and natural kil

155 er-cell immunoglobulin-like receptors (KIR), major histocompatibility complex class I chain-related g

156 erefore, the identification of antigens with major histocompatibility complex class I epitopes is a c

157 Major histocompatibility complex class I expression on M

158 features of perifascicular fiber atrophy and major histocompatibility complex class I expression.

159 ike receptor (iKIR) for which the respective major histocompatibility complex class I ligand is absen

160 usly generating peptides that could serve as major histocompatibility complex class I ligands, markin

161 Major histocompatibility complex class I molecules (MHC

162 ed by the interaction of Ly49 receptors with major histocompatibility complex class I molecules (MHC-

163 mor growth of melanoma cell lines expressing major histocompatibility complex class I molecules at hi

164 this study, we evaluated the contribution of major histocompatibility complex class I molecules to br

165 lasmic reticulum and subsequent loading onto major histocompatibility complex class I molecules to tr

166 Major histocompatibility complex class I polypeptide-rel

167 on of bacterial metabolites presented by the major histocompatibility complex class I-related molecul

168 utation led to loss of surface expression of major histocompatibility complex class I.

169 eract with peptides bound to the polymorphic major histocompatibility complex class Ia (MHC-Ia) and c

170 en, characterized by increased expression of major histocompatibility complex class II (approximately

171 e developed a mouse strain that lacks murine major histocompatibility complex class II (MHC II) and i

172 Inoculation with M. canis also decreased major histocompatibility complex class II (MHC-II) antig

173 Mtb has been reported to block major histocompatibility complex class II (MHC-II) antig

174 r (CIITA) is essential for the expression of major histocompatibility complex class II (MHC-II) genes

175 Major histocompatibility complex class II (MHC-II) molec

176 Major histocompatibility complex class II (MHC-II) molec

177 en presentation in addition to the classical major histocompatibility complex class II (MHC-II) pepti

178 ific for mouse CMV (MCMV) epitopes and use a major histocompatibility complex class II (MHC-II) tetra

179 ncodes the beta subunit of the non-classical major histocompatibility complex class II (MHC-II)-like

180 ologous antigen-specific CD4(+) T cells in a major histocompatibility complex class II (MHC-II; HLA-D

181 A polymorphism at beta57 in some major histocompatibility complex class II (MHCII) allele

182 se to alpha-syn fibrils, with attenuation of major histocompatibility complex class II (MHCII) and pr

183 lymphoid cell (ILC3)-intrinsic expression of major histocompatibility complex class II (MHCII) is reg

184 The major histocompatibility complex class II (MHCII) is ubi

185 ate in DC-to-MC molecule transfers including major histocompatibility complex class II (MHCII) protei

186 utoimmune-disease-relevant peptides bound to major histocompatibility complex class II (pMHCII) molec

187 gin when naive CD4(+) T cells engage peptide+major histocompatibility complex class II and co-stimula

188 ent with AZD1480 inhibited alpha-SYN-induced major histocompatibility complex Class II and inflammato

189 (SEB) is a superantigen that cross-links the major histocompatibility complex class II and specific V

190 UW-3/Cx) to induce infertility in mice whose major histocompatibility complex class II antigen was re

191 ed 44 epitopes that are predicted to be good major histocompatibility complex class II binders and at

192 Major histocompatibility complex class II binding and T-

193 targeting class II transactivator attenuates major histocompatibility complex class II expression on

194 or X, two transcription factors dedicated to major histocompatibility complex class II expression, su

195 o Mtb antigen processing rather than peptide-major histocompatibility complex class II loading.

196 We used major histocompatibility complex class II mismatched C57

197 teria, had stronger myocardial expression of major histocompatibility complex class II molecule and e

198 esenting a high density of peptides bound to major histocompatibility complex class II molecules (pMH

199 enabled the presentation of self antigens by major histocompatibility complex class II molecules in a

200 Wild-type LCs upregulated major histocompatibility complex class II molecules, mig

201 om internalized antigens in combination with major histocompatibility complex class II molecules.

202 oximately 30-50%) in expression of CD11b and major histocompatibility complex class II on both monocy

203 Furthermore, silencing of major histocompatibility complex class II reduces alloge

204 ation of VZV-specific CD4(+) T cells with an major histocompatibility complex class II tetramer (epit

205 Direct ex vivo staining with peptide-major histocompatibility complex class II tetramers enab

206 rturbed formation of the SEB.T-cell receptor.major histocompatibility complex class II trimer.

207 Moreover, the number of mast cells, major histocompatibility complex class II+, or CD11b+ im

208 Major histocompatibility complex class II, a marker of m

209 ating factor, and intragraft transcripts for major histocompatibility complex class II, Toll-like rec

210 can cross-link the T cell receptor (TCR) and major histocompatibility complex class II, triggering a

211 cluded restoration of mature macrophages and major histocompatibility complex class II-expressing den

212 ssed LMO2, CD58, and stromal-1-signature and major histocompatibility complex class II-signature gene

213 Major histocompatibility complex E (MHC-E) is a highly c

214 in fine-mapping of challenging regions, e.g. major histocompatibility complex for schizophrenia.

215 llects and expertly curates sequences of the major histocompatibility complex from non-human species

216 /c) and highly (Balb/c in C57BL/6) stringent major histocompatibility complex fully mismatched mouse

217 n and non-human leukocyte antigen genes of 3 major histocompatibility complex gene classes but not at

218 lfactory receptor, ATP-binding cassette, and major histocompatibility complex genes.

219 ssemblies to provide 100 completely resolved major histocompatibility complex haplotypes and to resol

220 Those results revealed two major histocompatibility complex haplotypes associated w

221 erential localization of DCs specialized for major histocompatibility complex I (MHC I) and MHC II pr

222 pes, the peptides that bind to non-classical major histocompatibility complex Ib Qa-1 molecules and a

223 ns and tumour neo-antigens in the context of major histocompatibility complex II (MHCII) are highly d

224 polyclonal stimulation, and displayed lower major histocompatibility complex II expression by antige

225 induced lysosome tubulation and secretion of major histocompatibility complex II in macrophages and d

226 Major histocompatibility complex II tetramers correspond

227 an increased number of microglia expressing major histocompatibility complex II.

228 subsets, resident cardiac MHCII(LO)CCR2(-) (major histocompatibility complex II/C-C motif chemokine

229 r directly or related to the function of the Major Histocompatibility Complex in a number of differen

230 we investigate the plasticity of a class II major histocompatibility complex in the absence of a bou

231 Continuous contact with self-major histocompatibility complex ligands is essential fo

232 performed in mice across varying degrees of major histocompatibility complex mismatch combinations.

233 ixed-chimerism model receiving BCNU across a major histocompatibility complex mismatch.

234 globulin exhibited >100-day survival of full major histocompatibility complex mismatched allografts,

235 We performed major histocompatibility complex mismatched aorta to car

236 underwent nonmyeloablative conditioning and major histocompatibility complex mismatched BMT with or

237 R engages a peptide bound to the restricting major histocompatibility complex molecule (pMHC), it tra

238 lf and foreign peptide antigens presented in major histocompatibility complex molecules (pMHC) is ess

239 ntigenic peptides within class I or class II major histocompatibility complex molecules (pMHCI or pMH

240 elements to ablate EC expression of class II major histocompatibility complex molecules and with it,

241 Ablation of endothelial cell class II major histocompatibility complex molecules by small inte

242 t recognize peptide antigens associated with major histocompatibility complex molecules expressed on

243 s (TCRs) recognize agonist peptides bound to major histocompatibility complex molecules on antigen-pr

244 of T cell responses is complex and involves major histocompatibility complex molecules on transplant

245 as processors of antigen for presentation by major histocompatibility complex molecules, recent findi

246 ce of interleukin-21 and enriched by peptide-major histocompatibility complex multimer-guided cell so

247 specific CD8 T cells were tracked down using major histocompatibility complex multimers against the i

248 Of the 110 non-major histocompatibility complex multiple sclerosis-asso

249 -domain antibody specific for human class II major histocompatibility complex products and used it to

250 ope with the extremely polymorphic nature of major histocompatibility complex products within the spe

251 (HLA)-DQ2.5 (DQA1*05/DQB1*02) is a class-II major histocompatibility complex protein associated with

252 ct with foreign antigens bound to alleles of major histocompatibility complex proteins (MHC) that the

253 HLA-A is a class I major histocompatibility complex receptor that presents

254 n signals for oligoclonal band status in the major histocompatibility complex region for the rs927164

255 Association within the major histocompatibility complex region was also observe

256 enabling antigen recognition independent of major histocompatibility complex restriction, while reta

257 "A-into-O" transplantation (major histocompatibility complex syngeneic) was modeled

258 a fundamental difference between the CD1 and major histocompatibility complex systems is that all hum

259 nsity single nucleotide polymorphisms of the major histocompatibility complex to precisely identify r

260 Finally, we observed the expression of major histocompatibility complex type I genes in a subse

261 utable to infiltration of activated class II major histocompatibility complex(+) T cells.

262 rong signals of selection at lactase and the major histocompatibility complex, and in favor of blond

263 pes at numerous sites, often on incompatible major histocompatibility complex, and occurs in the cont

264 469 located on 6p22.1, and covering lncRNAs (major histocompatibility complex, class I, A (HLA-A) and

265 veral classically used exosome markers, like major histocompatibility complex, flotillin, and heat-sh

266 ctively present survivin peptides on class I major histocompatibility complex, had significantly dimi

267 Ever since the discovery of the major histocompatibility complex, scientific and clinica

268 compatibility complex-1 tail, and subsequent major histocompatibility complex-1 downregulation and im

269 the mu1 subunit of adaptor protein 1 and the major histocompatibility complex-1 tail, and subsequent

270 lerosis genetics, we performed genotyping of major histocompatibility complex-borne microsatellites a

271 ed lesion expression of inflammatory markers major histocompatibility complex-class II and IL6, lesio

272 High target peptide-major histocompatibility complex-I (pMHC) affinity and T

273 es presented by the evolutionarily conserved major histocompatibility complex-like molecule MR1.

274 To elucidate major histocompatibility complex-linked systemic scleros

275 an informative clinically relevant RIC mouse major histocompatibility complex-matched alloHCT model b

276 We investigated a murine model of major histocompatibility complex-matched multiple minor

277 ger leukocytes (but not the parenchyma) were major histocompatibility complex-matched to the recipien

278 topic transplants were performed using minor major histocompatibility complex-mismatched B6.C-H2 dono

279 Using the major histocompatibility complex-mismatched mouse orthot

280 parenchyma and the passenger leukocytes were major histocompatibility complex-mismatched to the recip

281 rk Agouti rat and Balb mouse donors to fully major histocompatibility complex-mismatched Wistar Furth

282 in kidney allograft rejection using a fully major histocompatibility complex-mismatched, life-sustai

283 er kernel support vector machines to predict major histocompatibility complex-peptide binding.

284 gh-order feature interactions for predicting major histocompatibility complex-peptide binding.

285 161(+) MAIT cells, surface expression of the major histocompatibility complex-related protein 1 (MR1)

286 e used to confirm DSAs' specificity for allo-major histocompatibility complex.

287 n of Parkinson's disease with alleles of the major histocompatibility complex.

288 The major-histocompatibility-complex-(MHC)-class-I-related m

289 TCR) to functionally engage multiple peptide-major histocompatibility complexes (pMHC) are unclear.

290 ted with autoimmune disease-relevant peptide-major histocompatibility complexes (pMHC) blunted autoim

291 In searching for peptide-loaded major histocompatibility complexes (pMHCs), they must so

292 to functionally engage with multiple peptide-major histocompatibility complexes (pMHCs), we examined

293 itopes through interactions with peptide and major histocompatibility complexes (pMHCs).

294 acilitate chimerism and achieve tolerance in major histocompatibility disparate recipients have been

295 timal peptide repertoire for presentation by major histocompatibility (MHC) class I molecules (pMHCs

296 ion through recognition of peptides bound to major histocompatibility molecules (pMHC).

297 Class I major histocompatibility molecules were the first ligand

298 enic lymphocytes, and utilization of peptide-major histocompatibility multimers, along with imaging t

299 rol endosomal generation of peptide/class II major histocompatibility protein (MHC-II) complexes; the

300 ings suggest that T cell receptor (TCR)-self-major histocompatibility protein (pMHC) interactions lim